Experts Highlight Emerging Strategies and Unmet Needs in Mantle Cell Lymphoma
Dr. Lore Gruenbaum, PhD, recently discussed the evolving landscape of mantle cell lymphoma (MCL) in a presentation titled “New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons.” She highlighted fresh perspectives on treatment options, clinical endpoints, and the underlying biology of the disease.
The commentary emphasized that these new insights are broadening the therapeutic horizon for MCL and aim to tackle critical unmet needs that patients currently face.
Overall, the discussion points to a growing focus on research and collaboration to turn these emerging concepts into practical, effective therapies for the lymphoma community.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons”
read at onclive ↗
comments(0)
5-min edit window · permanent after that